These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 18683068)
21. First report of the use of meglumine antimoniate for treatment of canine leishmaniasis in a pregnant dog. Spada E; Proverbio D; Groppetti D; Perego R; Grieco V; Ferro E J Am Anim Hosp Assoc; 2011; 47(1):67-71. PubMed ID: 21164165 [TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum. Valladares JE; Riera C; Alberola J; Gállego M; Portús M; Cristòfol C; Franquelo C; Arboix M Vet Parasitol; 1998 Feb; 75(1):33-40. PubMed ID: 9566092 [TBL] [Abstract][Full Text] [Related]
23. [Leishmaniasis: hospital and population-based incidence, and asymptomatic infection. A disease that is still with us]. Bellido-Blasco JB; Arnedo-Pena A; Romeo-García MA; Herrero-Carot C Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):136-7. PubMed ID: 19254647 [No Abstract] [Full Text] [Related]
24. Leishmania infantum infection rates in Phlebotomus perniciosus fed on naturally infected dogs under antimonial treatment. Gradoni L; Maroli M; Gramiccia M; Mancianti F Med Vet Entomol; 1987 Oct; 1(4):339-42. PubMed ID: 2979550 [TBL] [Abstract][Full Text] [Related]
25. Serological and parasitological follow-up in dogs experimentally infected with Leishmania infantum and treated with meglumine antimoniate. Riera C; Valladares JE; Gállego M; Aisa MJ; Castillejo S; Fisa R; Ribas N; Carrió J; Alberola J; Arboix M Vet Parasitol; 1999 Jul; 84(1-2):33-47. PubMed ID: 10435789 [TBL] [Abstract][Full Text] [Related]
26. Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime) and the recombinant Leish-110f + MPL-SE vaccine to treat canine visceral leishmaniasis. Miret J; Nascimento E; Sampaio W; França JC; Fujiwara RT; Vale A; Dias ES; Vieira E; da Costa RT; Mayrink W; Campos Neto A; Reed S Vaccine; 2008 Mar; 26(12):1585-94. PubMed ID: 18328956 [TBL] [Abstract][Full Text] [Related]
27. Changes in serum anti-Leishmania antibody concentrations measured by time-resolved immunofluorometric assays in dogs with leishmaniosis after treatment. Cantos-Barreda A; Escribano D; Martínez-Subiela S; Pardo-Marín L; Segarra S; Cerón JJ Vet Immunol Immunopathol; 2018 Apr; 198():65-69. PubMed ID: 29571520 [TBL] [Abstract][Full Text] [Related]
28. Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol. Manna L; Corso R; Galiero G; Cerrone A; Muzj P; Gravino AE Parasit Vectors; 2015 May; 8():289. PubMed ID: 26017164 [TBL] [Abstract][Full Text] [Related]
29. Glomerulonephritis in dogs with canine leishmaniasis. Benderitter T; Casanova P; Nashkidachvili L; Quilici M Ann Trop Med Parasitol; 1988 Aug; 82(4):335-41. PubMed ID: 3252757 [TBL] [Abstract][Full Text] [Related]
30. Pancreatitis associated with N-methyl-glucamine therapy in a dog with leishmaniasis. Aste G; Di Tommaso M; Steiner JM; Williams DA; Boari A Vet Res Commun; 2005 Aug; 29 Suppl 2():269-72. PubMed ID: 16244972 [No Abstract] [Full Text] [Related]
31. Low dose glucantime therapy in Leishmania viannia braziliensis (Lvb) infections. Costa JM; Marsden PD Rev Soc Bras Med Trop; 1988; 21(2):85-6. PubMed ID: 3249826 [No Abstract] [Full Text] [Related]
32. Paraoxonase activity as a tool for clinical monitoring of dogs treated for canine leishmaniasis. Rossi G; Ibba F; Meazzi S; Giordano A; Paltrinieri S Vet J; 2014 Jan; 199(1):143-9. PubMed ID: 24188864 [TBL] [Abstract][Full Text] [Related]
33. Owners' experiences of administering meglumine antimoniate injections to dogs with leishmaniosis: An online questionnaire study. de Jong MK; van Eijk D; Broere F; Piek CJ Vet Rec; 2024 Jun; 194(11):e4089. PubMed ID: 38809570 [TBL] [Abstract][Full Text] [Related]
34. Variation of proteinuria in dogs with leishmaniasis treated with meglumine antimoniate and allopurinol: a retrospective study. Pierantozzi M; Roura X; Paltrinieri S; Poggi M; Zatelli A J Am Anim Hosp Assoc; 2013; 49(4):231-6. PubMed ID: 23690493 [TBL] [Abstract][Full Text] [Related]
35. The effect of intravenous or subcutaneous administration of meglumine antimonate (Glucantime) in dogs with leishmaniasis. A randomized clinical trial. Slappendel RJ; Teske E Vet Q; 1997 Mar; 19(1):10-3. PubMed ID: 9225422 [TBL] [Abstract][Full Text] [Related]
36. The renal transplant patient with visceral leishmaniasis who could not tolerate meglumine antimoniate-cure with ketoconazole and allopurinol. Hueso M; Bover J; Serón D; Gil-Vernet S; Rufí G; Alsina J; Grinyó JM Nephrol Dial Transplant; 1999 Dec; 14(12):2941-3. PubMed ID: 10570102 [No Abstract] [Full Text] [Related]
37. Update on therapy and prevention of canine leishmaniasis. Apostolopoulos N; Mitropoulou A; Thom N; Moritz A Tierarztl Prax Ausg K Kleintiere Heimtiere; 2018 Oct; 46(5):315-322. PubMed ID: 30541172 [TBL] [Abstract][Full Text] [Related]
39. Leishmania infantum-specific IgG, IgG1 and IgG2 antibody responses in healthy and ill dogs from endemic areas. Evolution in the course of infection and after treatment. Solano-Gallego L; Riera C; Roura X; Iniesta L; Gallego M; Valladares JE; Fisa R; Castillejo S; Alberola J; Ferrer L; Arboix M; Portús M Vet Parasitol; 2001 Apr; 96(4):265-76. PubMed ID: 11267753 [TBL] [Abstract][Full Text] [Related]
40. Low dosage combination of meglumine antimoniate plus allopurinol as first choice treatment of infantile visceral leishmaniasis in Italy. di Martino L; Mantovani MP; Gradoni L; Gramiccia M; Guandalini S Trans R Soc Trop Med Hyg; 1990; 84(4):534-5. PubMed ID: 2091347 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]